Eli Lilly Acquires AtaiBeckley to Expand Mental Health Portfolio
In July 2026, Eli Lilly (LLY) announced the acquisition of AtaiBeckley for $2.8 billion upfront and up to an additional $1 billion in milestone payments. This move is part of Lilly's strategy to expand its pipeline beyond weight loss drugs like Mounjaro and Zepbound into mental health treatments. Lilly already has a phase 3 program focused on depression using brenipatide, which shares similar biology with its diabetes medications. AtaiBeckley’s lead asset is BPL-003, an intranasal formulation of the psychedelic compound 5-MeO-DMT in late-stage trials for treatment-resistant depression (TRD). Another promising candidate from Atai is VLS-01, a DMT-based dissolving film expected to report phase 2b results by year-end. While these new programs may not immediately contribute significant revenue compared to Lilly’s blockbuster drugs, they represent long-term growth opportunities. The mental health market for depression treatments could expand if successful therapies gain broader adoption.
